AIFM2 and colorectal carcinoma: In summary, their work identifies the SLC6A8-creatine-ERK2-FSP1 axis as a previously unknown immune-evasion mechanism for CRC in the TME, confirming that targeting anti-ferroptotic pathways is a promising therapeutic option as it induces immune cells activity and improves ICB therapy in preclinical experiments [120].